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Background: Given the high prevalence of diabetes, guidelines are updated frequently to reflect optimal treatment
recommendations. Our study aims to measure the response of primary care physicians to changes in choice of
initial therapy for patients with type 2 diabetes in relationship to a change in Canadian Diabetes Association (CDA)
Guidelines in 2008. We also assessed patients’ and physicians’ factors which may affect this change.
Methods: Historical cohort study of primary care physicians’ participating in an electronic medical record research
network in Quebec, Canada. 111 primary care physicians and 1279 newly treated patients with diabetes with a
prescription of an oral hypoglycemic agent (OHA) between January 20 2003 and December 29 2011 were included.
Multivariate GEE logistic regression was used to estimate the impact of guideline change on treatment choice
controlling for patients’ and physicians’ characteristics.
Results: After the new CDA guidelines, there was an increase in incident use of metformin from 89.7% to 94.6%
(OR 1.86, 95% CI 1.20-2.90) with an accompanying reduction in the use of thiazolidinediones (OR 0.21, 95% CI 0.08-0.55),
and reduction in the initiation of sulfonylureas (OR 0.78, 95% CI 0.43-1.09). Physicians’ attitudes to evidence-based
practice did not significantly modify response to a change in guidelines recommendations. However, older patients
and those with renal failure were less likely to receive metformin.
Conclusions: Metformin initiation in newly diagnosed diabetes patients has increased post 2008 CDA guidelines.
However, due to the nature of the study design, we can not determine whether the observed change in metformin
prescribing was causally related to the change in the guideline.
Keywords: Type 2 diabetes, Metformin, Guidelines adherence, Medical informaticsBackground
Over the last few decades, demographic and lifestyle
changes have together contributed to the growing burden
of diabetes worldwide. In Canada alone, more than 9 mil-
lion individuals have been diagnosed with diabetes or pre-
diabetes and over 40,000 Canadians die annually with dia-
betes as a contributing factor [1]. The disease is associated* Correspondence: ting-yu.wang@mail.mcgill.ca
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reproduction in any medium, provided the orwith excess morbidities — including atherosclerosis, ne-
phropathy, retinopathy, cardiovascular disease and depres-
sion [2,3] — as well as early mortality, therefore leading to
high socio-economic cost. Recent estimates suggest that by
2020, diabetes will cost nearly 16.9 billion (CAD) annually
[1]. Given the complexity of chronic diseases, guidelines are
developed to synthesize new scientific evidence into recom-
mendations that will facilitate optimal disease management.
However in many instances, patients do not achieve recom-
mended care [4-6]. In diabetes, guidelines are published
regularly but published studies have revealed low adherencetd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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physicians’ non-adherence) [7-9].
In its latest clinical practice guidelines (October 2008)
[10], the Canadian Diabetes Association (CDA) recom-
mended metformin as the initiating treatment for all pa-
tients newly diagnosed with type 2 diabetes, regardless of
individual characteristics. The change was made based on
its effectiveness in lowering blood glucose, its relatively
mild side effect profile (no hypoglycemia or weight gain)
and its demonstrated benefit in overweight patients [11].
This differed from the previous CDA guidelines (2003),
which had recommended starting with a sulfonylurea, an
alpha-glucosidase inhibitor, or metformin for individuals
with a BMI of less than 25, and metformin specifically for
individuals with a BMI of over 25 [12]. Prior to the most
recent (2008) guidelines, a population-based administrative
database study of seniors showed that approximately 75%
of diabetics aged 65 or over in Ontario were prescribed
metformin as their first oral hypoglycemic agent (OHA)
[13]. Due to the simplified 2008 CDA guidelines, we would
expect to see an increase in its initiation rate. We used this
opportunity of a guideline change to estimate the change
in physicians’ approach to the treatment of diabetes in re-
sponse to guidelines changes as well as patients’ and physi-
cians’ factors that may influence guidelines adherence.
Methods
Context
The study was conducted in Quebec, Canada, where all
residents have insurance for medical and hospital care
through the Régie de l’Assurance Maladie du Québec
(RAMQ). Prescription drugs are covered by the provincial
insurance agency for seniors (age over 65) [14], social as-
sistance recipients, and those not insured through their
employer. In 2003, MOXXI, an experimental community-
based electronic health record and clinical information
system, was the first to link to these databases and inte-
grate this information into electronic health record sys-
tems to support clinical decision-making [15]. The
MOXXI electronic health record includes: 1) a problem
list that is automatically generated from diagnostic codes
within daily updates of medical services claims, treatment
indications entered at the time of drug prescribing, and
manual entries; 2) a drug profile that shows prescribed
and dispensed drugs, ED visits and hospitalizations in the
past 12 months, and 3) an electronic prescribing tool that
requires mandatory entry of treatment indication (from a
list of on- and off-label indications), and documentation of
the reason for drug discontinuations and dose changes.
Data generated by the MOXXI electronic health record
have been validated and used in a number of studies
[15-18]. The MOXXI system provided us with the first op-
portunity to investigate how changes in CDA guideline
recommendation for initial treatment of type 2 diabetesaffected physician prescribing practices. This study has
been approved by our institutional review board (McGill
University Institutional Review Board).
Design and study population
A dynamic historical cohort study was conducted compar-
ing newly treated patients with type 2 diabetes in the pre-
2008 guidelines period with those started on therapy in the
post-2008 period by family physicians in the MOXXI sys-
tem. Among the patients participating in the MOXXI re-
search program, patients were eligible if they had a
diagnosis of type 2 diabetes, and were newly started on an
OHA between 2003 and 2011, defined as having no prior
use of an antidiabetic agent in the past two years. Patients’
diagnosis of type 2 diabetes was defined based on their pre-
scription of an OHA and a treatment indication for dia-
betes entered on MOXXI electronic health record by the
treating physician.
Patients who were not covered by the RAMQ drug in-
surance plan were excluded, as there would be incom-
plete information on prior use of OHA. Patients who
had a history of gestational diabetes, who were under
the age of 18 and who were started on metformin with-
out a diagnosis of diabetes in the past 5 years were ex-
cluded from the study.
Canadian diabetes guideline change
Prior to the new guidelines, overweight patients would be
started on metformin as first agent; however, no specific
agent was recommended for those who had a BMI of less
than 25 [12]. In 2008, metformin became the initial OHA
due to its effectiveness in lowering blood glucose without
causing weight gain or hypoglycemia [10,11]. In addition,
metformin has a good safety profile with minimal side
effects.
Each patient in the cohort was classified as being started
on therapy in the pre- versus post- 2008 guidelines period,
in accordance with the date the drug was prescribed. Al-
though the new CDA guidelines were published in Sep-
tember 2008, we set the date of January 1 2008 as the cut-
off for the post-guideline period because guidelines up-
dates are often discussed at conferences prior to the actual
publication date (for example, CDA October 24–27,
2007), or by the CDA Guideline Dissemination and Imple-
mentation Committee. In addition, evidence of the bene-
fits of metformin (no hypoglycemia or weight gain) was
published well before the guidelines publication (UKPDS
34) [11] and information likely disseminated in seminars.
Patient characteristics
To control for confounding by potential differences in the
characteristics of patients started on therapy in the pre and
post guidelines change period, we measured age, gender,
and renal and cardiovascular co-morbidities (peripheral
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failure and cerebrovascular disease) documented in the pa-
tient’s electronic medical record.
Physician characteristics and attitudes to
evidence-based practice
To test the hypothesis of whether physicians with
evidence-based orientation are more compliant to guide-
lines, we used the evidence scale from the Evidence-
Practicality-Conformity questionnaire completed by each
physician at the time of enrollment [19-21]. The evidence
scale is created by summing Likert scale ratings from six of
the 17 questionnaire items (each question score ranging
from 1–5; score range 6–30). Higher scores on this scale
have been associated with clinical guidelines compliance
and less off-label prescribing in prior studies [19-21]. In
addition, we measured physician sex and years of practice
experience as both are associated with physicians’ prescrib-
ing behaviour [22].
Outcome
The primary outcome was the choice of initial hypo-
glycemic therapy, measured using data on prescriptions
and dispensed drugs from both the MOXXI and RAMQ
database. Oral hypoglycemic agents were grouped into
their respective classes: metformin (being the only biguan-
ide was labelled under its generic name), sulfonylurea
[(SU) glicalizide, glimeperide, glyburide, tolbutamide],
thiazolidinediones [(TZD) pioglitazone, rosiglitazone] and
others [alpha-1 glucosidase inhibitor (acarbose), megliti-
nides (repaglinide), DPP4-inhibitor (sitagliptin)]. We clas-
sified each patient as being started on metformin (yes vs.
no), as well as by the specific class of therapy they
received.
Analysis
To assess whether there was a difference in the proportion
of patients with type 2 diabetes who were initiated on met-
formin before and after the publication of the 2008 CDA
guidelines, we used multivariate logistic regression. As pa-
tients were clustered within physician, we used a general-
ized estimating equation (GEE) framework, where patient
was the unit of analysis, physician was the clustering factor,
and an exchangeable correlation structure was used to ac-
count for dependence among observations. Prescription of
metformin (yes vs no) was the binary outcome variable,
and patient’s age, sex and the presence or co-morbid car-
diovascular and renal disease were included as potential
confounders. To assess whether physicians’ with more
positive attitudes towards evidence-based practice were
more likely to modify their prescribing behaviour in re-
sponse to a guideline, we included the evidence-based
practice score (grouped into tertiles of <20, 20–23, and
>23) and guidelines period (pre vs post 2008) as interactionterms in the model. We also included physician gender
and practice experience in the model as a potential con-
founders of evidence-based attitudes.
In secondary analyses, we assessed whether there were
differences in the classes of OHA used in the pre and post
2008 guidelines period, with the expectation that any in-
crease in metformin use would be accompanied by a re-
duction in treatment initiation with other classes of OHA.
In this model, treatment period was used as the binary
outcome variable (pre vs post 2008 guidelines), and start-
ing class of therapy was used as a multicategorical dummy
variable, using metformin as the reference category. The
model was adjusted for patient and physician characteris-
tics using multivariate GEE models, as outlined previously.
All analyses were performed using SAS software 9.2.
Results
Baseline characteristics
Of the 8170 prescribed with an OHA between January 20
2003 and December 29 2011, 5438 adults were fully cov-
ered by the RAMQ drug insurance plan, and had no previ-
ous diagnosis of gestational diabetes. Of these, 1316
(16.1%) were newly started on an OHA. Within this group,
34 (2.6%) were prescribed metformin without a diagnosis
of diabetes. Therefore, 1279 (15.7%) patients were included
in the study population. There were a total of 111 physi-
cians in the study. However, a total of 19 physicians did
not complete the Evidence-Practicality-Conformity ques-
tionnaire, and were excluded from the multivariate analysis
of interaction effects.
Overall, 49.2% of the study population were male, 53.4%
were over 65 years of age, 7.4% had cardiovascular prob-
lems, and 1.3% had renal impairment, 92% were started on
one agent (Table 1). Overall, 54.1% of the physicians were
male, 58.7% has an evidence score of 20–23. Patients and
primary care physicians in the pre versus post guideline pe-
riods were similar in their characteristics.
Metformin use pre vs post guideline
After the publication of the new CDA guidelines, there
was an absolute increase in incident use of metformin of
4.9% (pre-guidelines 89.7%; post-guidelines 94.6%; OR:
1.86, 95% CI 1.20-2.90) (Table 2 and 3). Metformin use in-
creased even after adjusting for patient and physician
characteristics (OR: 1.86, 95% CI 1.20-2.90). Although
physicians with higher scores (upper vs. bottom tertile) on
the evidence-based practice scale were more likely to pre-
scribe metformin (OR 1.16, 95% CI 0.55-2.46), it was not
statistically significant. A trend of increasing use of met-
formin was seen particularly from 2007 to 2011 compared
with 2003 (Figure 1).
Among the 1177 (92.0%) patients who were started on
metformin, patients younger than 65 years old had 64%
more odds in receiving metformin (OR 1.64, 95% CI 1.09-
Table 1 Characteristics of patients with Type 2 diabetes
started on oral hypoglycemic pre and post Canadian
Diabetes Association (CDA) 2008 guidelines, and their
primary care physicians
No (%) of patients
or mean ± SD
Pre Post Overall
Patient characteristics n=670 n=609 n=1,279
Gender
• Female 341 (50.9) 309 (50.7) 650 (50.8)
• Male 329 (49.1) 300 (49.3) 629 (49.2)
Age
• <65 276 (41.2) 282 (46.3) 558 (43.6)
• ≥65 394 (58.8) 327 (53.7) 721 (53.4)
Co-morbidities
• Cardiovascular 45 (6.7) 40 (6.6) 95 (7.4)




• 1 610 (91.0) 567 (93.1) 1177 (92.0)
• ≥2 60 (9.0) 42 (6.9) 102 (8.0)
Physician characteristics n=95 n=73 n=111
Gender
• Female 45 (47.4) 30 (41.1) 51 (45.9)
• Male 50 (52.6) 43 (58.9) 60 (54.1)
Practice experience
(in years) (mean, SD)
22 (8.1) 23.4 (7.6) 21.95 (8.08)
Evidence score n=83 n=68 n=92
(mean, SD) 21.1 (2.4) 21.2 (2.5) 21.2 (2.51)
• <20 20 (24.7) 18 (26.5) 23 (25.0)
• 20-23 49 (60.5) 38 (55.9) 54 (58.7)
• >23 12 (14.8) 12 (17.7) 15 (16.3)
Table 2 Multivariate analysis of patients’ characteristics
and started on metformin (Yes/No)
No (%) of patients
or mean ± SD
Multivariate
analysis*
Yes No OR (95% CI) p value
Patient
characteristics
n = 1177 n = 102
Gender
• Male 582 (49.5) 47 (46.1) 1.00 [Reference]
• Female 595 (50.6) 55 (53.9) 0.85 (0.55-1.32) 0.48
Age
• ≥65 649 (55.1) 72 (70.6) 1.0 [Reference]
• <65 528 (44.9) 30 (29.4) 1.64 (1.09-2.48) 0.02
Co-morbidities
Cardiovascular
• No 1101 (93.5) 93 (91.2) 1.00 [Reference]
• Yes 76 (6.5) 9 (8.8) 0.78 (0.37-1.66) 0.52
Renal
• No 1167 (99.1) 95 (93.1) 1.00 [Reference]
• Yes 10 (0.9) 7 (6.9) 0.14 (0.05-0.40) <0.0001
Drugs
Number of OHA
• ≥2 93 (7.9) 9 (8.8) 1.00 [Reference] 0.83





• Male 59 (54.1) 34 (63.0) 1.00 [Reference]
• Female 50 (45.9) 20 (37.0) 1.21 (0.66-2.23) 0.53
Practice experience
(in years) (mean, SD)




• <20 22 (24.4) 14 (26.9) 1.00 [Reference]
• 20-23 53 (58.9) 31 (59.6) 0.71 (0.38-1.34) 0.29
• >23 15 (16.7) 7 (13.5) 1.16 (0.55-2.46) 0.69
Evidence guidelines†
2008 CDA guidelines
• Pre 601 (51.1) 69 (67.7) 1.00 [Reference]
• Post 576 (48.9) 33 (32.4) 1.86 (1.20-2.90) 0.01
Note: OHA Oral hypoglycemic agent, CDA Canadian Diabetes Association.
*Multivariate analysis done for patients’ gender, age and co-morbidities,
guidelines, MD evidence scale, gender, practice experience and drugs.
†Model cannot converge when an interaction term involving guideline and
MD evidence scale (categorical) were included.
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among patients with renal disease (OR 0.14; 95% CI 0.05-
0.40). Concurrent with an increase in the use of metfor-
min post-guidelines, there was a 79% reduction in the
odds of initiation of TZD (OR 0.21, 95% CI 0.08-0.55) and
a statistically non-significant 32% decrease in the odds of
treatment initiation with SU (OR 0.68, 95% CI 0.43-1.09)
(Table 3).
Discussion
To our knowledge, this is the first study to examine how
a change in guidelines for diabetes treatment was tem-
porally associated with the choice of starting therapy for
newly treated type 2 diabetics. Pre-2008 guidelines, simi-
lar to the population-based Ontario study [13], our
paper showed a high initiation rate of metformin. Post-guidelines, we showed an absolute increase of 4.9% in its
use. This higher initiation of metformin was associated
with a decreased prescription of thiazolidinediones and
sulfonylureas, which suggested physicians’ compliance to
the change of guidelines. However, around the same
Table 3 Multivariate analysis for OHA classes pre and post CDA 2008 guidelines
No (%) of patients or mean ± SD Multivariate analysis*
Pre Post OR (95% CI) p value
n = 670 n = 609
Classes of OHA†
• Metformin ± other‡ 601 (89.7) 576 (94.6) 1.00 [Reference]
• TZD 18 (2.7) 3 (0.5) 0.21 (0.08-0.55) 0.001
• Sulfonylurea 54 (8.1) 27 (4.4) 0.68 (0.43-1.09) 0.11
• Other‡ 3 (0.5) 4 (0.7) 1.44 (0.29-7.06) 0.65
Note: OHA Oral hypoglycemic agent, TZD Thiazolidinediones, CDA Canadian Diabetes Association.
*Multivariate analysis done for patients’ gender, age and co-morbidities, guidelines, MD evidence scale, gender, practice experience and drugs.
†Patients initiated on more than 1 drug (with no Metformin) were counted in both classes.
‡Includes Alpha-1 glucosidase inhibitor (Acarbose), DPP-4 inhibitor (Sitagliptin) and Meglitinides.
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of rosiglitazone with an increased risk of myocardial in-
farction and a possible increase in the risk of death from
cardiovascular causes [23,24]. Subsequently, a black box
warning issued in October 2007 by drug regulatory agen-
cies in both Canada and the United States may have been
an important contributing cause to change in prescribing
practices. However, given both TZD and SU decreased (al-
though not statistically significant due to the small sample
size), accompanied by a rise in metformin initiation, it is
plausible that a change in treatment guidelines contrib-
uted to this trend. It addition, it was also seen by Shah
et al. [25] that the major decline of TZD actually occurred
in 2007.
Guidelines are published every few years with the aim to
help physicians incorporate new scientific evidence into
clinical practice and improve the standard of care. How-
ever, the translation of evidence into clinical practice is
often slow, unpredictable and incomplete [26]. Prior stud-
ies have demonstrated only mild to moderate improvement
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Figure 1 The graph shows the proportions of patients started on
metformin (out of the total oral hypoglycemic agents initiated for
patients with newly diagnosed type 2 diabetes) and the 95%
confidence intervals for calendar years 2003–2011.the case of diabetes, some studies investigating physicians’
adherence to diabetes guidelines revealed low to moderate
compliance [8,30-33]. This is likely due to the complexity
of the disease and by the number of medications required
[9]. Contrary to these studies, our study demonstrated high
initiation of metformin in incident patients with type 2 dia-
betes, and a further increase post-guidelines change. In
addition, when yearly metformin initiation rate was ana-
lyzed, we saw an increasing trend since 2007. This higher
compliance rate could be due to the abundance of research
published prior to the guidelines indicating the benefits of
metformin [11,34].
As expected, the initiation of metformin was lower in
those with renal failure and who are older than 65 years
old. The use of metformin in the elderly has been heavily
debated [35,36]. The lower use could be due to the reluc-
tance of physicians to prescribe to the elderly due to the
side effects related to metformin (gastrointestinal upset,
including diarrhea, nausea, vomiting and flatulence) and
the rare possibility of lactic acidosis in those with renal
failure [37]. While age created a difference in drug treat-
ment choice, more evidence-based physicians were not
more likely to change practice. This could be due to the
high initiation rate of metformin (89.7%) pre-guideline, as
well as limited power to detect differences in effect.
Strengths and limitations
To our knowledge, our study is the first to examine how a
change in guidelines for diabetes treatment was temporally
associated with the choice of starting therapy for newly
treated type 2 diabetics. We were able to include a large
number of patients over eight years. Having the ability to
examine physicians’ prescriptions instead of administrative
data that represent drugs dispensed enabled us to look at
the physicians’ actual prescribing decisions and exclude
medication compliance bias.
Our study has several limitations. This research used a
selective cohort of primary physicians: only primary care
physicians who elected to use an electronic medical record
system, and their knowledge and intended use of the new
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not fully covered by RAMQ drug insurance were excluded
(33.2% of the adult diabetic population); thus, this could ex-
clude patients who were younger (in Quebec, patients older
than 65 are mostly covered by RAMQ [14]) or who had
higher socio-economic status, where prescribing decisions
could have been different. In addition, the use of metformin
in patients with incident diabetes was already high prior to
guidelines, making the impact less than predicted despite
the change in guideline. An analysis of metformin prescrip-
tion rates for obese versus non-obese individuals would
have been valuable, but could not be performed due to the
lack of patients’ body mass index in the MOXXI database.
Our study showed that there was only a small percent-
age of patients with co-morbid illness (7.4% patients
with cardiovascular disease and 1.3% with renal illness).
This could either be attributed to healthier primary care
population than those typically studied in hospital popu-
lations, or alternatively, incomplete chart documentation
of co-morbid conditions.
Conclusions
Unlike previous studies showing low adherence to guide-
lines [8,38], this study demonstrated an increase in the initi-
ation of metformin as first line treatment instead of
sulfonylurea or thiazolidinediones by primary care physi-
cians after the new CDA 2008 guidelines. However, due to
the nature of the study design, we can not determine
whether the observed change in metformin prescribing was
causally related to the change in the guideline. The next
step would be to examine the compliance in other aspect
of diabetes management and sustainability of guidelines ad-
herence among primary care physicians and specialists.
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